SAN
FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) management is scheduled to present at
upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference in
New York City on Monday, September 9, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time
- Stifel Virtual Immunology and Inflammation Summit on
Tuesday, September 17, 2024 at
12:30 p.m. Eastern Time /
9:30 a.m. Pacific Time
The presentations will be accessible via webcast through links
posted on the Investor Events section of the Nektar website:
https://ir.nektar.com/events-and-presentations/events. The webcasts
will be available for replay until October
9, 2024 and October 17, 2024,
respectively.
About Nektar Therapeutics
Nektar Therapeutics is
a clinical-stage biotechnology company focused on developing
treatments that address the underlying immunological dysfunction in
autoimmune and chronic inflammatory diseases. Nektar's lead product
candidate, rezpegaldesleukin (NKTR-358), is a novel, first-in-class
regulatory T cell stimulator being evaluated in two Phase
2b clinical trials, one in atopic
dermatitis and one in alopecia areata. Our pipeline also includes a
preclinical candidate NKTR-0165, which is a bivalent tumor necrosis
factor receptor type II agonist antibody. Nektar, together with
various partners, is also evaluating NKTR-255, an investigational
IL-15 receptor agonist designed to boost the immune system's
natural ability to fight cancer, in several ongoing clinical
trials. Nektar is headquartered in San
Francisco, California. For further information,
visit www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian
Wu of Nektar Therapeutics
628-895-0661
For Media:
David Rosen
of Argot Partners
(212) 600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302236329.html
SOURCE Nektar Therapeutics